References
- Babelova, A., B. C. Burckhardt, and W. Wegner, et al. 2015. “Sex-Differences in Renal Expression of Selected Transporters and Transcription Factors in Lean and Obese Zucker Spontaneously Hypertensive Fatty Rats.” Journal of Diabetes Research. doi:10.1155/2015/483238.
- Bhosle, M. J., and R. Balkrishnan. 2007. “Drug Reimportation Practices in the United States.” Therapeutics and Clinical Risk Management 3 (1): 41–46. doi:10.2147/tcrm.2007.3.issue-1.
- Chen, C., R. Dubin, and M. C. Kim. 2014. “Orphan Drugs and Rare Diseases: A Scientometric Review (2000–2014).” Expert Opinion on Orphan Drugs 2: 709–724. doi:10.1517/21678707.2014.920251.
- Cohen, J. P. 2014. “Patient Access to Orphan Drugs Faces New Set of Challenges.” Accessed April 20, 2015. http://formularyjournal.modernmedicine.com/formulary-journal/news/patient-access-orphan-drugs-faces-new-set-challenges?page=full
- Doiron, D., D. G. Fiebig, M. Johar, and A. Suziedelyte. 2015. “Does Self-Assessed Health Measure Health?” Applied Economics 47: 180–194. doi:10.1080/00036846.2014.967382.
- Doležal, T., and J. Klimeš. 2013. “Financing for Drugs for Rare Diseases – Current Situation and What Next? Institute for Health Economics and Technology Assessment.” Presented in the Chamber of Deputies- 7th meeting of the Subcommittee on Health of the Orphan drugs economy, Prague, September 27.
- E15.cz. 2013. “VZP Published Costs For Drugs Such Centers.” Accessed April 20, 2015. http://zdravi.e15.cz/clanek/mlada-fronta-zdravotnicke-noviny-zdn/vzp-uverejnila-naklady-na-centrove-leky-470276
- European Commission. 2012. “1,000th Designation of an Orphan Medicinal Product: Improving the Lives of Patients.” Accessed April 20, 2015. http://europa.eu/rapid/press-release_IP-12-573_en.htm?locale=en
- Public Health Europe – European Commission. 2012. “The Website of European Commission.” Accessed April 20, 2015. http://ec.europa.eu/health/rare_diseases/policy/index_en.htm
- EURORDIS. 2012. “Website of Non-Governmental Patient-Driven Alliance of Patient Organisations.” Accessed April 20, 2015. www.eurordis.org
- Fernandez, J.-M., R. M. Stein, and A. W. Lo. 2012. “Commercializing Biomedical Research through Securitization Techniques.” Nature Biotechnology 30: 964–975. doi:10.1038/nbt.2374.
- Fiminska, Z. 2014. “Orphan Drugs: Way to Go for Pharma?” Accessed April 20, 2015. http://social.eyeforpharma.com/research-development/orphan-drugs-way-go-pharma
- Fričová, V., and K. Fričová. 2010. “Medicaments in Group ‘orphan’.” Praktické Lékárenství 3: 139–143.
- Gandjour, A. 2015. “A Model to Optimize Investments in Health Technologies, Quality of Care and Research.” Applied Economics 47 (20): 2031–2039. doi:10.1080/00036846.2014.995366.
- Hall, A. K., and M. R. Carlson. 2014. “The Current Status of Orphan Drug Development in Europe and the US.” Intractable & Rare Diseases Research 3 (1): 1–7. doi:10.5582/irdr.3.1.
- Hughnes, W., W. Palma, A. Schurman, and S. Simoens. 2012. “Paying for the Orphan Drug System: Break or Bend? Is It Time for a New Evaluation System for Payers in Europe to Take Account of New Rare Disease Treatments?” Orphanet Journal of Rare Disease 7: 74. doi:10.1186/1750-1172-7-74.
- Hutchings, A., C. Schey, R. Dutton, F. Achana, and K. Antonov. 2014. “Estimating the Budget Impact of Orphan Drugs in Sweden and France 2013–2020.” Orphanet Journal of Rare Diseases 9: 22. doi:10.1186/1750-1172-9-22.
- Ilbars, H., D. K. Irmak, and H. Akan. 2014. “Orphan Drugs: R&D Challenges with Updates from Turkey and Middle East Countries.” Journal for Clinical Studies 6 (2): 58–63.
- Jackson, L. 2014. “5 Orphan Drug Biotech Stocks to Buy with Big Upside Potential.” Accessed April 20, 2015. http://247wallst.com/healthcare-business/2014/09/25/5-orphan-drug-biotech-stocks-to-buy-big-upside-potential/
- Jeffery, M., and S. R. Mukku “Orphan Drug Pricing and Access – Current Situation and Future Trends in EU.” Poster at Conference of International Society for Pharmacoeconomics & Outcomes Research – European Conference, Berlin, Germany. 2012 doi:10.1016/j.jval.2012.08.658.
- Kager, L., U. Pötschger, and S. Bielack. 2010. “Review of Mifamurtide in the Treatment of Patients with Osteosarcoma.” Therapeutics and Clinical Risk Management 6: 279—286.
- Kumar, S., and K. Grimmer. 2005. “Nonsteroidal Antiinflammatory Drugs (NSAIDs) and Physiotherapy Management of Musculoskeletal Conditions: A Professional Minefield?” Therapeutics and Clinical Risk Management 1 (1): 69–76. doi:10.2147/tcrm.1.1.69.53596.
- Labadie, O. W., and Y. Zhou. 2010. “The US Orphan Drug Act: Rare Disease Research Stimulator or Commercial Opportunity?” Health Policy 95 (2–3): 216–228. doi:10.1016/j.healthpol.2009.12.001.
- Lenk, C., and G. Duttge. 2014. “Ethical and Legal Framework and Regulation for Off-Label Use: European Perspective.” Therapeutics and Clinical Risk Management 10: 537—546.
- Macek, M. 2012. “Rare Diseases. Institute of Biology and Medical Genetics 2nd Faculty of Medicine and the University Hospital. Sami Rare Strong Together.” Presented at the Chamber of Deputies Seminar ‘Rare Diseases - Sami rare, strong together’, Prague, May 22.
- Marešová, P., H. Mohelská, J. Dolejš, and K. Kuča. 2015. “Socio-economic Aspects of Alzheimer’s Disease.” Current Alzheimer Research 12 (9): 903–911. doi:10.2174/156720501209151019111448.
- Maresova, P., H. Mohelska, and K. Kuca. 2015. “Cooperation Policy of Rare Diseases in the European Union.” Procedia – Social and Behavioral Sciences 171: 1302–1308. doi:10.1016/j.sbspro.2015.01.245.
- Marešová, P., M. Penhaker, A. Selamat, and K. Kuča. 2015. “The Potential of Medical Device Industry in Technological and Economical Con-text.” Therapeutics and Clinical Risk Management 11: 1505—1514.
- Mezher, M. 2015. “Orphan Drugs in the EU: A Record-Breaking Year.” Accessed November 20, 2015. http://www.raps.org/Regulatory-Focus/News/2015/01/13/21063/Orphan-Drugs-in-the-EU-A-Record-Breaking-Year/
- Mohelská, H., P. Marešová, M. Vališ, and K. Kuča. 2015. “Alzheimer Disease and Its Treatment Costs – Case Study in the Czech Republic.” Neuropsychiatric Disease and Treatment 11: 2349—2354. (IF 1,74).
- Moors, E. H. M., and J. Faber. 2007. “Orphan Drugs: Unmet Societal Need for Non-Profitable Privately Supplied New Products.” Research Policy 36 (3): 336–354. doi:10.1016/j.respol.2006.12.006.
- Orphanet a. 2014. “Orphan Drugs in Japan.” Accessed April 20, 2015 http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=st_education_education_aboutorphandrugs_jap
- Orphanet b. 2014. “Orphan Drugs in Singapore.” Accessed April 20, 2015. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=st_education_education_aboutorphandrugs_sin
- Orphanet d. 2014. “Orphan Drugs in Europe.” Accessed April 20, 2015. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=st_education_education_aboutorphandrugs_eur
- Orphanet e. 2014. “Orphan Drugs in USA.” Accessed April 20, 2015. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=st_education_education_aboutorphandrugs_usa
- Orphanet f. 2014. “Orphan Drugs in Australia.” Accessed April 20, 2015. http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=st_education_education_aboutorphandrugs_aus
- Schey, C., T. Milanova, and A. Hutchings. 2011. “Estimating the Budget Impact of Orphan Medicines in Europe: 2010–2020.” Orphanet Journal of Rare Diseases 6: 62. doi:10.1186/1750-1172-6-62.
- U.S. Food and Drug Administration. 2009. “Developing Orphan Products: FDA and Rare Disease Day.” Accessed April 20, 2015. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107293.htm
- General Health Insurance Company in the Czech Republic (VZP). 2012. “Costs are Rising and there is no Link Between Revenue and Expenditure. Infoservis 8(3): 23–26.
- Yenturk, N., B. Ulengin, and A. Cimenoglu. 2009. “An Analysis of the Interaction among Savings, Investments and Growth in Turkey.” Applied Economics 41 (6): 739–751. doi:10.1080/00036840601019000.